{"id":165792,"name":"JAZZ PHARMACEUTICALS, INC.","slug":"jazz-pharmaceuticals-inc","state":"CA","description":"Specialty pharmaceuticals","totalSpending":2010000,"filings":29,"yearlySpending":[{"year":2018,"income":180000},{"year":2019,"income":200000},{"year":2020,"income":320000},{"year":2021,"income":320000},{"year":2022,"income":320000},{"year":2023,"income":320000},{"year":2024,"income":200000},{"year":2025,"income":150000}],"firms":["AVENUE SOLUTIONS"],"lobbyists":["TRACY SPICER","MATTHEW FUENTES"],"issues":["HCR","CPT",null,"MMM","DEF"],"sampleDescriptions":["PL 114-255, 21st Century Cures Act, implementation; \n\nH.R. 4784, Lower Drug Costs Through Competition Act; \n\nS. 974/H.R. 2212, CREATES Act of 2015; \n\nH.R. 2051, FAST Generics; \n\nDrug safety issues; \n\nPrescription drug abuse; \n\nIssues related to opioids policies and offsets;\n\nH.R. 6, Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT for Patients and Communities Act); \n\nS. 3120, Helping to End Addiction and Lessen Substance Use Disorders Act of 2018 (HEAL Act of 2018);\n\nS. 2680, Opioid Crisis Response Act of 2018","Drug safety issues; \n\nPrescription drug abuse; \n\nIssues related to opioids policies and offsets;\n\nH.R. 965/ S. 340, CREATES Act of 2019","Drug safety issues; \n\nPrescription drug abuse; \n\nMonitor drug pricing legislation; \n\nH.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act;\n\nS. 1895, Lower Health Care Costs Act;\n\nH.R. 965/ S. 340, CREATES Act of 2019; \n\nS. 1416, Affordable Prescriptions for Patients Act of 2019","Drug safety issues; \n\nPrescription drug abuse; \n\nMonitor drug pricing legislation; \n\nH.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act;\n\nS. 1895, Lower Health Care Costs Act;\n\nH.R. 965/ S. 340, CREATES Act of 2019; \n\nS. 1416, Affordable Prescriptions for Patients Act of 2019;\n\nH.R. 1865, Consolidated Domestic and International Assistance Bill;\n\nH.R. 5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019","Drug safety issues; \n\nPrescription drug abuse; \n\nMonitor drug pricing legislation; \n\nH.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act;\n\nS. 1895, Lower Health Care Costs Act;\n\nS. 1416, Affordable Prescriptions for Patients Act of 2019;\n\nH.R. 5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019;\n\nH.R. 3, Elijah E. Cummings Lower Drug Costs Now Act;\n\nH.R. 748 (Public Law 116-136), CARES Act","Drug safety issues; \n\nPrescription drug abuse; \n\nMonitor drug pricing legislation; \n\nH.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act;\n\nS. 1895, Lower Health Care Costs Act;\n\nS. 1416, Affordable Prescriptions for Patients Act of 2019;\n\nH.R. 5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019;\n\nH.R. 3, Elijah E. Cummings Lower Drug Costs Now Act;\n\nPublic Law 116-136, CARES Act;\n\nH.R. 1425, Patient Protection and Affordable Care Enhancement Act (PPACEA)","Drug safety issues; \n\nPrescription drug abuse; \n\nMonitor drug pricing legislation; \n\nH.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act;\n\nS. 1895, Lower Health Care Costs Act;\n\nS. 1416, Affordable Prescriptions for Patients Act of 2019;\n\nH.R. 5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019;\n\nH.R. 3, Elijah E. Cummings Lower Drug Costs Now Act;\n\nPublic Law 116-136, CARES Act;\n\nH.R. 1425, Patient Protection and Affordable Care Enhancement Act (PPACEA);\n\nIssues related to Priority Review Voucher extension;\n\nH.R. 6800, The Heroes Act; \n\nH.R. 925, The Heroes Act","Drug safety issues; \n\nPrescription drug abuse; \n\nMonitor drug pricing legislation; \n\nH.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act;\n\nS. 1895, Lower Health Care Costs Act;\n\nS. 1416, Affordable Prescriptions for Patients Act of 2019;\n\nH.R. 5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019;\n\nH.R. 3, Elijah E. Cummings Lower Drug Costs Now Act;\n\nPublic Law 116-136, CARES Act;\n\nH.R. 1425, Patient Protection and Affordable Care Enhancement Act (PPACEA);\n\nIssues related to Priority Review Voucher extension;\n\nH.R. 6800, The Heroes Act; \n\nH.R. 925, The Heroes Act;\n\nH.R. 133, Consolidated Appropriations Act, 2021 (Public Law 116-260)","Drug safety issues; \n\nPrescription drug abuse; \n\nMonitor drug pricing legislation; \n\nContinue monitoring of Affordable Prescriptions for Patients Act of 2019 from 116th Congress ; \n\nContinue monitoring of Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 from 116th Congress; \n\nContinue monitoring of Elijah E. Cummings Lower Drug Costs Now Act from 116th Congress; \n\nContinue monitoring of Prescription Drug Pricing Reduction Act of 2019 from 116th Congress\n\nContinue monitoring Consolidated Appropriations Act, 2021 (PL 116-260);\n\nH.R. 1319, American Rescue Plan Act of 2021 (PL 117-2)","Drug safety issues; \n\nMonitor drug pricing legislation; \n\nContinue monitoring of Affordable Prescriptions for Patients Act of 2019 from 116th Congress; \n\nContinue monitoring of Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 from 116th Congress; \n\nContinue monitoring of Elijah E. Cummings Lower Drug Costs Now Act from 116th Congress; \n\nContinue monitoring of Prescription Drug Pricing Reduction Act of 2019 from 116th Congress;\n\nSenate Finance Committee Prescription Drug Pricing Reform Principles;\n\nImplementation of American Rescue Plan Act of 2021 (PL 117-2)","Issues related to patent thicketing","Drug safety issues; \n\nMonitor drug pricing legislation; \n\nContinue monitoring of Affordable Prescriptions for Patients Act of 2019 from 116th Congress; \n\nContinue monitoring of Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 from 116th Congress; \n\nContinue monitoring of Elijah E. Cummings Lower Drug Costs Now Act from 116th Congress; \n\nContinue monitoring of Prescription Drug Pricing Reduction Act of 2019 from 116th Congress;\n\nSenate Finance Committee Prescription Drug Pricing Reform Principles;\n\nImplementation of American Rescue Plan Act of 2021 (PL 117-2)\n\nH.R. 5376, Build Back Better Act; \n\nMonitor Possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, adding Medicare enhancements/supplemental benefits (hearing, dental, vision), addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform; \n\nProposed repeal of the CMS Rule on Most Favored Nation Model;\n\nDelay of the Rebate Rule","S. 1435, Affordable Prescriptions for Patients Act of 2021","Drug safety issues;\n\nMonitor drug pricing legislation;\n\nContinued monitoring drug pricing legislation, including S. 1435, Affordable Prescriptions for Patients Act; H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act; H.R. 3, Elijah E. Cummings Lower Drug Costs Now; Prescription Drug Pricing Reduction Act;\n\nSenate Finance Committee Prescription Drug Pricing Reform Principles;\n\nImplementation of American Rescue Plan Act of2021 (PL 117-2);\n\nH.R. 5376, Build Back Better Act; \n\nMonitor possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, adding Medicare enhancements/supplemental benefits (hearing, dental, vision), addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform; \n\nProposed repeal of the CMS Rule on Most Favored Nation Model; \n\nDelay of the Rebate Rule; \n\nPL 117-58 - Infrastructure Investment and Jobs Act (BIF) - issues related to rebate rule delay, repurposed Provider Relief Funds, Medicare savings from single source vial size drug policy and extension of mandatory sequester); \n\nPL-117-71 Protecting Medicare and American Families from Sequester Cuts Act - specifically:  6 months relief from 2% Medicare sequester, 4% statutory Pay-As-You-Go Act, 1 year relief of physician conversion factor cuts, 1 year delay of clinical lab (PAMA) cuts, delay of radiation oncology demo","Drug safety issues; Monitor drug pricing legislation; H.R. 5376, Build Back Better Act; Monitor Possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform; Issues related to reauthorization of FDA user fee bills including accelerated approval; H.R. 5585, The Advanced Research Project Agency-Health (ARPA-H) Act; Issues related to the White House Cancer Moonshot initiative; Consolidated Appropriations Act, 2022 (PL 117-103)","Drug safety issues; Monitor drug pricing legislation; H.R. 5376, Build Back Better Act; Monitor possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform; Issues related to FDA user fee reauthorization bills ( H.R. 7667, Food and Drug Amendments of 2022; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including accelerated approval, reimportation, and orphan drugs; H.R. 5585, The Advanced Research Project Agency-Health (ARPA-H) Act; Issues related to the White House Cancer Moonshot initiative; Consolidated Appropriations Act, 2022 (PL 117-103)","Drug safety issues; Monitor drug pricing legislation; Issues related to FDA user fee reauthorization bills ( H.R. 7667, Food and Drug Amendments of 2022; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including accelerated approval, reimportation, and orphan drugs; H.R. 5585, The Advanced Research Project Agency-Health (ARPA-H) Act; Issues related to the White House Cancer Moonshot initiative; Issues related to H.R. 5376, Inflation Reduction Act of 2022 (now PL 117-169) and implementation; Issues related to the Continuing Resolution, H.R. 6833","Drug safety, prescription drug abuse, drug pricing; Inflation Reduction Act of 2022 (PL 117-169); S. 4348, FDA Safety and Landmark Advancements Act; H.R. 7667, Food and Drug Amendments of 2022 H.R. 2617, Consolidated Appropriations Act, 2023","Drug safety, prescription drug abuse, value of prescription drugs; Expiring healthcare extenders; H.R. 4366, the Consolidated Appropriations Act, 2024 (P.L. 118-42); H.R. 2882, the Further Consolidated Appropriations Act, 2024 (P.L. 118-47)","Issues related to implementation of Inflation Reduction Act of 2022 (PL 117-169)"],"years":[2018,2019,2020,2021,2022,2023,2024,2025]}